A Preliminary Study on the Association of the Peroxisome Proliferator-Activated Receptor-Γ Gene Pro12Ala Polymorphism with the Efficacy of Pioglitazone

张琦,王晓霞,马征,王国英
DOI: https://doi.org/10.3321/j.issn:1006-6187.2007.03.013
2007-01-01
Abstract:Objective To study the association of peroxisome proliferator-activated receptor-γ(PPARγ)gene Pro12Ala polymorphism with the drug efficacy of pioglitazone. Methods A total of 112 type 2 diabetic patients were treated with pioglitazone (30 mg/qd) for 10 weeks. PPARγ gene Pro12Ala polymorphism was examined by using polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP). Results After pioglitazone treatment, the patients showed a significant decrease in FBG, HbA1c and TG, and an increase in HDL-C and BMI. After stratifying by PPARγ gene Pro12Ala polymorphism, there was a significant decrease in FBG, HbA1c, TG, DBP and SBP, but a significant increase in HDL-C and BMI in PP genotype group. In contrast, carriers with PA+AA genotype experienced a significant decrease only in FBG. Conclusions Pioglitazone may reduce the levels of plasma glucose and blood pressure, improve plasma lipid in type 2 diabetic patients, but may also cause the increase in their body weights. Those efficacies of pioglitazone may be associated with PPARγ gene Pro12Ala polymorphism.
What problem does this paper attempt to address?